Geho
Diabetes
NOACK
Australia
Biography
At P&G, Dr. Geho led the development of the first bis-phosphonate compounds for bone imaging (Osteoscan®) and metabolic bone disease (Didronel®) from preclinical studies, through clinical trials and FDA approval. Bis-phosponates are the class of drugs used for treating osteoporosis and cancer-related bone pain. Dr. Geho established P&G’s pharmaceutical research division.
Research Interest
Endocrinology
